How to buy BeyondSpring stock | $11.78

BeyondSpring Inc is a biotechnology business based in the US. BeyondSpring shares (BYSI) are listed on the NASDAQ and all prices are listed in US Dollars. BeyondSpring employs 61 staff and has a market cap (total outstanding shares value) of USD$432.5 million.

How to buy shares in BeyondSpring

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for BeyondSpring. Find the stock by name or ticker symbol: BYSI. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BeyondSpring reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$11.78, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of BeyondSpring, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of BeyondSpring. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

BeyondSpring share price

Use our graph to track the performance of BYSI stocks over time.

BeyondSpring shares at a glance

• Key figures

Information last updated 2020-12-26.

Latest market close	USD$11.78
52-week range	USD$9.38 - USD$18.83
50-day moving average	USD$12.1112
200-day moving average	USD$13.4665
Wall St. target price	USD$35.5
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.898

Buy BeyondSpring shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy BeyondSpring stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of BeyondSpring Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BeyondSpring price performance over time

Historical closes compared with the close of $11.78 from 2020-12-18

1 week (2021-01-08)	-6.66%
1 month (2020-12-16)	4.06%
3 months (2020-10-15)	-21.47%
6 months (2020-07-15)	-18.76%

1 year (2020-01-15)	-35.38%
2 years (2019-01-15)	-37.34%
3 years (2018-01-12)	25.74
5 years (2016-01-12)	N/A

BeyondSpring financials

Gross profit TTM	USD$0
Return on assets TTM	-103.49%
Return on equity TTM	-267.71%
Profit margin	0%
Book value	$0.788
Market capitalisation	USD$432.5 million

TTM: trailing 12 months

Shorting BeyondSpring shares

There are currently 923,876 BeyondSpring shares held short by investors – that's known as BeyondSpring's "short interest". This figure is 24.2% down from 1.2 million last month.

There are a few different ways that this level of interest in shorting BeyondSpring shares can be evaluated.

BeyondSpring's "short interest ratio" (SIR)

BeyondSpring's "short interest ratio" (SIR) is the quantity of BeyondSpring shares currently shorted divided by the average quantity of BeyondSpring shares traded daily (recently around 896966.99029126). BeyondSpring's SIR currently stands at 1.03. In other words for every 100,000 BeyondSpring shares traded daily on the market, roughly 1030 shares are currently held short.

However BeyondSpring's short interest can also be evaluated against the total number of BeyondSpring shares, or, against the total number of tradable BeyondSpring shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BeyondSpring's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 BeyondSpring shares in existence, roughly 20 shares are currently held short) or 0.0334% of the tradable shares (for every 100,000 tradable BeyondSpring shares, roughly 33 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BeyondSpring.

Find out more about how you can short BeyondSpring stock.

BeyondSpring share dividends

We're not expecting BeyondSpring to pay a dividend over the next 12 months.

BeyondSpring share price volatility

Over the last 12 months, BeyondSpring's shares have ranged in value from as little as $9.38 up to $18.83. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BeyondSpring's is 0.5803. This would suggest that BeyondSpring's shares are less volatile than average (for this exchange).

BeyondSpring overview

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.

Frequently asked questions

• What percentage of BeyondSpring is owned by insiders or institutions?

  Currently 71.545% of BeyondSpring shares are held by insiders and 6.224% by institutions.

• How many people work for BeyondSpring?

  Latest data suggests 61 work at BeyondSpring.

• When does the fiscal year end for BeyondSpring?

  BeyondSpring's fiscal year ends in December.

• Where is BeyondSpring based?

  BeyondSpring's address is: 28 Liberty Street, New York, NY, United States, 10005

• What is BeyondSpring's ISIN number?

  BeyondSpring's international securities identification number is: KYG108301006

• What is BeyondSpring's CUSIP number?

  BeyondSpring's Committee on Uniform Securities Identification Procedures number is: G10830100